94-5491. Prospective Grant of Exclusive Patent License

[Federal Register Volume 59, Number 47 (Thursday, March 10, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-5491]


[[Page Unknown]]

[Federal Register: March 10, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Prospective Grant of Exclusive Patent License

AGENCY: National Institutes of Health, Public Health Services, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license in limited fields of use to practice the 
inventions embodied in U.S. Patent 4,371,673 (formerly U.S. Patent 
Application 06/170,570) and its foreign counterparts, entitled ``Water 
Soluble Forms of Retinoids'' to Samuelsson & Wadstein Medicina AB 
having a place of business at Lund, Sweden. The patent rights in these 
inventions have been assigned to the United States of America
    The prospective exclusive license will be for the fields of skin 
care products for topical application and wound healing for topical 
application. It will be royalty-bearing and will comply with the terms 
and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective 
exclusive license may be granted unless, within sixty days from the 
date of this published notice, NIH receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    This invention relates to cyclodextrin complexes of retinoid-
polymers and complexes of retinoids with ether type derivatives of 
cyclodextrins. The U.S. patent issued on February 1, 1983 and contains 
both composition of matter and method of making claims to these 
complexes.

ADDRESSES: Requests for a copy of the above identified patent 
application, inquiries, comments and other materials relating to the 
contemplated license should be directed to: Mr. Mark Hankins, J.D., 
Office of Technology Transfer, National Institutes of Health, Box OTT, 
Bethesda, Maryland 20892 (telephone: [phone]; FAX: (301) 402-
0220). Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the grant of 
the contemplated license. Only written comments and/or applications for 
a license which are received by the NIH Office of Technology Transfer 
within sixty (60) days of this notice will be considered.

    Dated: February 16, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-5491 Filed 3-9-94; 8:45 am]
BILLING CODE 4140-01-M